Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Jennifer Frytak"'
Autor:
C. Lance Cowey, Nicholas J. Robert, Janet L. Espirito, Kalatu Davies, Jennifer Frytak, Israel Lowy, Matthew G. Fury
Publikováno v:
Cancer Medicine, Vol 9, Iss 20, Pp 7381-7387 (2020)
Abstract Prior studies of conventional chemotherapy or epidermal growth factor receptor inhibitors for advanced (ie, locally advanced cutaneous squamous cell carcinoma [laCSCC] or metastatic [mCSCC]) cutaneous squamous cell cancer enrolled ≤ 40 pat
Externí odkaz:
https://doaj.org/article/16fe8240e8cf433a9412df569003e488
Autor:
Kat Aguilar, Nicholas J. Robert, Jennifer Frytak, Brigham Walker, Kalatu Davies, Janet L. Espirito, Marley Boyd
Publikováno v:
JCO Clinical Cancer Informatics. :45-46
Autor:
Jad Hayes, Marcus A. Neubauer, Brigham Walker, Jennifer Frytak, Nicholas J. Robert, Lalan S. Wilfong
Publikováno v:
JAMA Netw Open
Importance Health insurers reimburse clinicians in many ways, including the ubiquitous fee-for-service model and the emergent shared-savings models. Evidence on the effects of these emergent models in oncological treatment remains limited. Objectives
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40002fa106f6ee0753cb959599b8ac6a
https://europepmc.org/articles/PMC7235689/
https://europepmc.org/articles/PMC7235689/
Autor:
Kendall Lee Stevinson, C. Lance Cowey, Jenny Black-Shinn, Jennifer Frytak, Scot Ebbinghaus, Frank Xiaoqing Liu, Marley Boyd
Publikováno v:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
The programmed death-1 inhibitor pembrolizumab has demonstrated efficacy and safety in clinical trials for treating advanced (unresectable/metastatic) melanoma. We investigated the real-world utilization of pembrolizumab and associated patient outcom
Publikováno v:
Journal of Cancer Policy. 29:100294
Background The Oncology Care Model (OCM) incentivized care coordination and cost-efficiency and has been associated with short-term care reductions, but its multi-year associations are less well-studied. Methods We used monthly provider-level claims
Autor:
Beloo Mirakhur, Jennifer Frytak, A. Scott Paulson, Susan Pitman Lowenthal, Patricia S. Fox, Fadi Braiteh, Marley Boyd, Xiaolong Jiao, Sonia Pulgar, David G. Cox
Publikováno v:
Pancreas. 47(2)
OBJECTIVE This study was conducted to understand treatment patterns and clinical outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients treated in a large community oncology network. METHODS This retrospective study used the McKe
Autor:
C. Lance Cowey, Kalatu Davies, Nicholas J. Robert, Matthew G. Fury, Janet L. Espirito, Jennifer Frytak, Israel Lowy
Publikováno v:
Journal of Clinical Oncology. 37:e21033-e21033
e21033 Background: Advanced CSCC is a term that encompasses the locally advanced (laCSCC) and metastatic (mCSCC) condition. For advanced CSCC patients who receive conventional anticancer systemic treatment, there are limited data regarding treatment
Autor:
Ancilla W. Fernandes, Melissa Pavilack, Eric Nadler, Jennifer Frytak, Jamyia Clark, Susan Amirian
Publikováno v:
Journal of Clinical Oncology. 36:9-9
9 Background: EGFR TKI therapy improves outcomes in pts with EGFRm+ NSCLC. NCCN guidelines recommend EGFRm testing for pts with NSCLC. Testing patterns and predictors of documented EGFRm testing were studied in a real-world setting. Methods: Adult pt
Autor:
Briana Ndife, Rohit Borker, Thomas Wilson, Janet L. Espirito, Nicholas J. Robert, Sameer R. Ghate, Whitney C. Rhodes, Jennifer Frytak, C. Lance Cowey, Antonio Nakasato
Publikováno v:
Journal of Clinical Oncology. 36:e21574-e21574
e21574Background: Adjuvant treatment options for stage III melanoma patients (pts) are increasing with the approval of new agents. Little has been reported about the real world treatment patterns i...
Autor:
Jennifer Frytak, Jeff P. Sharman, John M. Burke, Jenny Black-Shinn, Jamyia Clark, Janet Espirito
Publikováno v:
Blood. 128:4215-4215
Introduction: Treatment patterns and clinical outcomes in elderly patients with DLBCL treated outside of clinical trials are poorly characterized. A previous report from Medicare Claims data found that 28% of patients above the age of 66 were treated